Professional
Added to YB: 2024-01-24
Pitch date: 2024-01-24
NVO [bullish]
Novo Nordisk A/S
-55.78%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.3T
Pitch Price
DKK 669.68
Price Target
N/A
Dividend
3.91%
EV/EBITDA
8.10
P/E
11.43
EV/Sales
4.31
Sector
Pharmaceuticals
Category
growth
Show full summary:
Hermes Investment holding: Novo Nordisk ($NVO)
$NVO Wegovy obesity drug w/ semaglutide in high demand; SELECT trial: 20% heart risk reduction in obese adults; treats 36.4M, extends 1.9M lives; 30% on Wegovy lost 20%+ weight; addresses diabetes & obesity health impacts like heart disease, cancer; strong pipeline despite $LLY competition
Read full article (2 min)